ConsAMPHemo: A computational framework for predicting hemolysis of antimicrobial peptides based on machine learning approaches.

Journal: Protein science : a publication of the Protein Society
Published Date:

Abstract

Many antimicrobial peptides (AMPs) function by disrupting the cell membranes of microbes. While this ability is crucial for their efficacy, it also raises questions about their safety. Specifically, the membrane-disrupting ability could lead to hemolysis. Traditionally, the hemolytic activity of AMPs is evaluated through experiments. To reduce the cost of assessing the safety of an AMP as a drug, we introduce ConsAMPHemo, a two-stage framework based on deep learning. ConsAMPHemo performs conventional binary classification of the hemolytic activities of AMPs and predicts their hemolysis concentrations through regression. Our model demonstrates excellent classification performance, achieving an accuracy of 99.54%, 82.57%, and 88.04% on three distinct datasets, respectively. Regarding regression prediction, the model achieves a Pearson correlation coefficient of 0.809. Additionally, we identify the correlation between features and hemolytic activity. The insights gained from this work shed light on the underlying physics of the hemolytic nature of an AMP. Therefore, our study contributes to the development of safer AMPs through cost-effective hemolytic activity prediction and by revealing the design principles for AMPs with low hemolytic toxicity. The codes and datasets of ConsAMPHemo are available at https://github.com/Cpillar/ConsAMPHemo.

Authors

  • Peilin Xie
    Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen 518172, China.
  • Lantian Yao
    Warshel Institute for Computational Biology, The Chinese University of Hong Kong, Shenzhen, PR China, and also in the School of Science and Engineering, The Chinese University of Hong Kong, Shenzhen, PR China.
  • Jiahui Guan
    Nvidia, Boston, United States.
  • Chia-Ru Chung
    Department of Computer Science and Information Engineering, National Central University.
  • Zhihao Zhao
    Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, 2001 Longxiang Road, 518172 Shenzhen, China.
  • Feiyu Long
    Shenzhen Institute for Advanced Study, University of Electronic Science and Technology of China, Shenzhen, China.
  • Zhenglong Sun
    SUTD-MIT International Design Center, Singapore University of Technology and Design, Singapore. Electronic address: sunkurt@gmail.com.
  • Tzong-Yi Lee
  • Ying-Chih Chiang
    Kobilka Institute of Innovative Drug Discovery, School of Medicine, The Chinese University of Hong Kong, Shenzhen, China.